Today the Federal Minister for Health, the Hon Peter Dutton, announced that the cost of Everolimus for Tuberous Sclerosis will be subsidised by the government through the pharmaceutical benefits scheme (PBS). This medicine is approved in Australia for the treatment of subpendymal giant cell astrocytomas (SEGAs) and kidney angiomyolipomas (AMLs).
This announcement is the next stage after the successful submission to the PBAC. Everolimus is the first ever treatment specifically for Tuberous Sclerosis Complex (TSC) and inclusion on the PBS will make it accessible to those living with the impacts of this devastating disease.
You can read more about this new medicine on our mTOR inhibitors information sheet.
If you would like to discuss whether this medicine is a treatment option for you or your child you should talk to your doctor.
You can read more about the announcement at: